fluoropyrimidine, HER2 positivum,, oxaliplatin, Seagen Inc, tucatinib, Tukysa
Accelerata approbatio a FDA ad tucatinib cum trastuzumab pro cancro colorectali conceditur
Mense Februario 2023, Cibus et medicamentum Administrationis (FDA) approbationem tucatinib (Tukysa, Inc. Seagen) et trastuzumab curationem generis RAS silvestris-typi HER2-positivi colorectalis cancri curando diffudit vel rem.
fluoropyrimidine, gastroesophageal coniunctas (GEJ) ADENOCARCINOMA, KEYTRUDA, Merck Belize & Co, Pembrolizumab, trastuzumab
FDA-positivum HER2 Pembrolizumab suscipit probatus accelerato stomachum cancer
August MMXXI: Pembrolizumab (Keytruda, Merck Belize & Co.) Cum tandem coniunctim afficient vniuersa trastuzumab, fluoropyrimidine- et platinum-chemotherapy quibus datum est accelerato acquisitae probat per Cibus et medicamentis Administration pro abietes illius ..
Londini myers, CHECKMATE DCXLIX,, fluoropyrimidine, niveumab, Mirabilis, quibus platinum-chemotherapy
Probatus per FDA Nivolumab praeter chemotherapy est et esophageal ADENOCARCINOMA de CARDIACUS cancer metastatic
Augusti MMXXI enim aetatis vel metastatic stomachum cancer coniungitur gastroesophageal cancer et esophageal ADENOCARCINOMA Cibus et medicamentis Administration approbata nivolumab (Opdivo Bristol myers Lorem,) nempe una ..